ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2017 conference call and webcast on Tuesday, March 13, 2018, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 7997444#:
|USA: +1 8338186807||United-Kingdom: +44 02031070289|
|Switzerland: +080 0836508||Germany: +49 06922224728|
|France: +33 0176748988||Belgium: +32 024003547|
|Sweden: +46 0856619361||Finland: +358 0972519310|
|Netherlands: +31 0207075547||Spain: +34 914142503|
The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/qa7wj9by
An archived replay of the call will be available for 7 days by dialing (US & Canada): +1 833 818 6807, (UK): +44(0) 203 107 0289, (France): +33(0)1 726 74 89 88, (Spain): +34 91412503, Conference ID # 7997444#
An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 trial in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
The Ruth Group
+1 646 536 7012
+1 508 280 6592
+33 1 44 71 98 52
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
MEYDAN-ONE12.12.2018 16:00 | Pressemeddelelse
Dubai’s Meydan One Takes Shape
JANSSEN12.12.2018 15:58 | Pressemeddelelse
New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
MA-FRISS12.12.2018 15:02 | Pressemeddelelse
FRISS Joins Duck Creek Partner Ecosystem to Provide Risk and Fraud Detection Solutions to Property & Casualty Insurers Worldwide
DC-VELODYNE-LIDAR-INC.12.12.2018 14:32 | Pressemeddelelse
David Hall Honored as “2018 Inventor of the Year” by Intellectual Property Owners Education Foundation
ALTASCIENCES12.12.2018 14:15 | Pressemeddelelse
Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
NY-TAKEDA/NY-ACADEMY12.12.2018 14:02 | Pressemeddelelse
Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum